Neprilysin inhibition for heart failure.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update.Alzheimer's research & therapy · 2024
   Review
2. Epigenetic gene expression links heart failure to memory impairment.EMBO molecular medicine · 2021
   Article
3. Dementia and the heart failure patient.European heart journal supplements : journal of the European Society of Cardiology · 2019
   Article
4. Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications.International journal of molecular sciences · 2019
   Review
5. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Journal of biological engineering · 2018
   Review
6. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Clinical science (London, England : 1979) · 2016
   Review
7. Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.PloS one · 2016
   Article

Corrections and comments

• Commented on by
  Neprilysin inhibition for heart failure.2014
• Comment on
  Angiotensin-neprilysin inhibition versus enalapril in heart failure.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as